Independence Wealth Advisors LLC Invests $841,000 in IQVIA Holdings Inc. $IQV

Independence Wealth Advisors LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,733 shares of the medical research company’s stock, valued at approximately $841,000.

Other institutional investors have also modified their holdings of the company. Physician Wealth Advisors Inc. lifted its position in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares in the last quarter. Westside Investment Management Inc. grew its stake in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in shares of IQVIA in the third quarter worth $30,000. Atlantic Union Bankshares Corp purchased a new position in shares of IQVIA in the 3rd quarter valued at $36,000. Finally, Root Financial Partners LLC purchased a new stake in IQVIA during the 3rd quarter worth $43,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IQV shares. Citigroup cut their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Mizuho set a $215.00 target price on IQVIA in a research note on Monday, February 23rd. Evercore reiterated an “outperform” rating and set a $225.00 target price on shares of IQVIA in a report on Thursday, February 5th. UBS Group decreased their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Buy” and a consensus price target of $229.13.

IQVIA Stock Performance

Shares of IQVIA stock opened at $165.91 on Monday. The firm has a market cap of $28.16 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 1.60 and a beta of 1.40. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm’s 50-day simple moving average is $194.13 and its 200-day simple moving average is $206.19. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same period in the previous year, the company earned $3.12 earnings per share. IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.